NCT05586971 (EURELIA2) is a Phase 3 clinical trial of Tigulixostat in Gout, sponsored by LG Chem.

Who is sponsoring NCT05586971?

NCT05586971 is sponsored by LG Chem.

What drugs are being tested in NCT05586971?

Interventions in NCT05586971: Tigulixostat, Allopurinol, Placebo.

What condition does NCT05586971 study?

NCT05586971 studies Gout, Hyperuricemia, Gout Flare, Tophi.

Is NCT05586971 still recruiting?

NCT05586971 is currently completed. Last updated 22 July 2025.

Last reviewed 2025-07-22 · How we verify

NCT05586971: EURELIA2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Completed Phase 3 Last updated 22 July 2025

What this trial tests

Phase 3 trial testing Tigulixostat in Gout in 2,202 participants. Completed in 6 May 2025.

Timeline

30 March 2023

Primary endpoint
6 May 2025

6 May 2025

Quick facts

Lead sponsor	LG Chem
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	2,202
Start date	30 March 2023
Primary completion	6 May 2025
Estimated completion	6 May 2025
Sites	279 locations across Italy, Colombia, Malaysia, Taiwan, Poland, South Korea, Philippines, New Zealand

Drugs / interventions tested

Tigulixostat — full drug profile →
Allopurinol (ALLOPURINOL) — full drug profile →
Placebo

Conditions studied

Gout — all drugs for Gout →
Hyperuricemia — all drugs for Hyperuricemia →
Gout Flare — all drugs for Gout Flare →
Tophi — all drugs for Tophi →

Sponsor

LG Chem — full company profile →

Who can join

Adults 18 to 85, any sex, with Gout or Hyperuricemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials.
Singh A, Singh K, Sharma A, Kaur K, et al · · 2023 · cited 10× · PMID 37974965 · DOI 10.1039/d3md00316g
Heterocyclic compounds as xanthine oxidase inhibitors for the management of hyperuricemia: synthetic strategies, structure-activity relationship and molecular docking studies (2018-2024).
Singh A, Debnath R, Chawla V, Chawla PA. · · 2024 · cited 6× · PMID 38911168 · DOI 10.1039/d4md00072b
Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies.
Saag KG, Dalbeth N, Hsu CY, Kuo CF, et al · · 2025 · cited 1× · PMID 39929260 · DOI 10.1016/j.cct.2025.107843

Verify or expand the search:

Other trials of Tigulixostat

Trials testing the same drug.

NCT07414394 — Tigulixostat (IBI128) vs Febuxostat in Gout · Phase 3 · recruiting
NCT06189404 — Effect of Tigulixostat on the Pharmacokinetics of Theophylline · Phase 1 · completed
NCT05586958 — Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients · Phase 3 · completed

Other recruiting trials for Gout

Currently open trials in the same condition.

NCT07414394 — Tigulixostat (IBI128) vs Febuxostat in Gout · Phase 3 · recruiting
NCT07367971 — Drug-Drug Interaction Study of ABP-671 in Gout Patients · Phase 1 · recruiting
NCT07346079 — Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares · Phase 4 · recruiting
NCT07089875 — A Study of Dotinurad Versus Allopurinol in Participants With Gout · Phase 3 · recruiting
NCT05507723 — Tight Control of Gouty Arthritis Compared to Usual Care · NA · recruiting

Other LG Chem trials

Trials by the same sponsor.

NCT07396844 — The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Voluntee · Phase 1 · not yet recruiting
NCT07399470 — A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagl · Phase 1 · active not recruiting
NCT07333742 — A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metfor · Phase 1 · completed
NCT06921395 — Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulat · Phase 4 · recruiting
NCT06743997 — A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05586971 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LG Chem
Last refreshed: 22 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05586971.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing